Email :
Contact : (321) 445-1969

A Review article on clinical trials on hybrid drugs and nanohybrid technologies in drug development that combat cancer. Share


Cancer is one of the highly prevalent diseases worldwide that affects different organs of the body, leading to the rapid and uncontrolled division of cells, forming a mass of tumor cells. There are several conventional therapies available for cancer diagnosis like X-ray, magnetic resonance, CT, tomography, ultrasound and endoscopy, and cancer treatment such as radiotherapy, chemotherapy, surgery. But, there is a growing need for the novel drug delivery system, which can target only cancerous cell and does not affect the healthy cells. Nanotechnolo gy has come up with one of the drug delivery system to work at nano-scale, based in the area of bioengineering, medicine and pharmacology. Based on previous experience, engineers are trying to evolve a new treatment system, which can reduce the side effects occurring due to conventional procedures. Hybrid drug and Nanohybrid technology are the most advance technology for the effective treatment of cancer. Hybrid drugs are being designed to combine two anti-cancer agents so that they can act more effectively and nanodrugs are being developed to improve the delivery of therapeutic agent to the cancerous site, without causing side effects to the healthy cells. In this review, we have discussed about several in-vitro research and clinical research, conducted on several hybrid drugs (p63-53o Specific and Non-genetic IAP-dependent Protein Eraser and Hybrid 9) and nanodrugs such as pegylated liposomal doxorubicin, albumin-bound paclitaxel, and N-(-2 hydroxypropyl) methacrylamide-doxorubicin (N-(2-hydroxypropyl) methacrylamide) copolymer-Mesochlorin e6), which present to be the effective treatment, gaining importance in the cancer therapeutics.

Download Pdf